Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Total Liabilities (2016 - 2025)

Viking Therapeutics (VKTX) has disclosed Total Liabilities for 12 consecutive years, with $76.7 million as the latest value for Q4 2025.

  • Quarterly Total Liabilities rose 173.39% to $76.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $76.7 million through Dec 2025, up 173.39% year-over-year, with the annual reading at $76.7 million for FY2025, 173.39% up from the prior year.
  • Total Liabilities hit $76.7 million in Q4 2025 for Viking Therapeutics, up from $26.4 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $76.7 million in Q4 2025 to a low of $8.8 million in Q4 2021.
  • Historically, Total Liabilities has averaged $22.4 million across 5 years, with a median of $18.5 million in 2023.
  • Biggest YoY gain for Total Liabilities was 173.39% in 2025; the steepest drop was 40.3% in 2025.
  • Year by year, Total Liabilities stood at $8.8 million in 2021, then soared by 164.38% to $23.2 million in 2022, then fell by 13.51% to $20.1 million in 2023, then skyrocketed by 39.72% to $28.0 million in 2024, then soared by 173.39% to $76.7 million in 2025.
  • Business Quant data shows Total Liabilities for VKTX at $76.7 million in Q4 2025, $26.4 million in Q3 2025, and $32.4 million in Q2 2025.